The use of virtual environments to prevent or treat behavioral addictions: A systematic review.

J Psychiatr ResMay 13, 2026 (epub)
Clinical ResearchPsychiatry

Nelson Bruno de Almeida Cunha, Miguel Peixoto, Artemisa R Dores

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the effectiveness of Virtual Reality (VR) and Augmented Reality (AR) interventions for preventing and treating Gambling Disorder (GbD) and Gaming Disorder (GmD) in a population of 498 individuals. The review found that multiple VR therapy sessions significantly reduced craving and anxiety in GbD, while VR/AR interventions improved symptoms and coping skills in GmD, highlighting the potential of immersive technologies in addiction management.

Key findings

  • Multiple VR therapy sessions significantly reduced craving and anxiety in Gambling Disorder.
  • VR/AR interventions reduced symptom severity and gaming time in Gaming Disorder.
  • Immersive technologies enhanced self-regulation and reduced addictive behaviors across both disorders.

Why it matters

Understanding the role of VR and AR in treating behavioral addictions is crucial as these technologies may offer innovative, effective strategies for prevention and management, addressing limitations of traditional approaches.

Source

PubMed · PMID 42155316

Published in J Psychiatr Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.